Duration of Belimumab Therapy and Timing of Initiation as Predictors of Clinical Outcomes in Childhood-Onset Systemic Lupus Erythematosus: A Real-World Retrospective Study
{{output}}
Introduction: Belimumab is the only biologic approved for childhood-onset systemic lupus erythematosus (cSLE), yet evidence on the optimal timing of initiation and duration of therapy remains limited. This study aimed to evaluate... ...
